Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 5/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436105 | 0.83 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL7958461 | 0.83 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL28843568 | 0.83 | PNP (0.39) | MEN1KMT2AALDH1A1PNPGDA | |
| SCHEMBL21539483 | 0.80 | GDA (0.36) | MEN1KMT2AALDH1A1PNPGDA | |
| SCHEMBL28976276 | 0.79 | PNP (0.39) | ALDH1A1PNPGDA | |
| SCHEMBL7801077 | 0.78 | PNP (0.36) | ALDH1A1PNPGDAPDE2A | |
| SCHEMBL5053844 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1PNPGDA | |
| SCHEMBL4560085 | 0.77 | GDA (0.53) | MEN1KMT2AALDH1A1PNPGDA | |
| SCHEMBL10998 | 0.77 | GDA (0.53) | MEN1KMT2AALDH1A1PNPGDA | |
| SCHEMBL2352519 | 0.76 | PNP (0.43) | MEN1KMT2AALDH1A1PNPGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220170062-A1 | RNA CAPPING METHOD, PRODUCTION METHOD FOR MODIFIED RNA, AND MODIFIED RNA | KYOTO UNIVERSITY (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7626014-B2 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | ALNYLAM PHARMACEUTICALS (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | ADAR, FUT5, CSGALNACT1 | MEN1 3064/4885KMT2A 4099/4885ALDH1A1 2165/4885 |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | MEN1 3710/4885KMT2A 3054/4885ALDH1A1 3617/4885 |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | MEN1 3422/4885KMT2A 3846/4885ALDH1A1 2715/4885 |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | MEN1 4779/4885KMT2A 831/4885ALDH1A1 1576/4885 |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | MEN1 4670/4885KMT2A 971/4885ALDH1A1 1280/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | MEN1 3710/4885KMT2A 3054/4885ALDH1A1 3617/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | MEN1 4638/4885KMT2A 1035/4885ALDH1A1 2096/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | MEN1 4584/4885KMT2A 792/4885ALDH1A1 1623/4885 |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | MEN1 4779/4885KMT2A 831/4885ALDH1A1 1576/4885 |
| US-20220170062-A1 | RNA CAPPING METHOD, PRODUCTION METHOD FOR MODIFIED RNA, AND MODIFIED RNA | RNGTT, NSUN2, NSUN3 | MEN1 3630/4885KMT2A 1774/4885ALDH1A1 1923/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | MEN1 1138/4885KMT2A 1839/4885ALDH1A1 4588/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | MEN1 3710/4885KMT2A 3054/4885ALDH1A1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.